Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Depreciation & Amortization (CF) (2016 - 2023)

Tenax Therapeutics' Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $3022.0 for Q4 2017.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 31.64% to $3022.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $13621.0, a 28.13% decrease, with the full-year FY2023 number at $8000.0, up 55.55% from a year prior.
  • Depreciation & Amortization (CF) hit $3022.0 in Q4 2017 for Tenax Therapeutics, down from $3143.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for TENX hit a ceiling of $39257.0 in Q2 2014 and a floor of $3022.0 in Q4 2017.
  • Historically, Depreciation & Amortization (CF) has averaged $20139.0 across 5 years, with a median of $19500.0 in 2014.
  • Biggest five-year swings in Depreciation & Amortization (CF): rose 3.18% in 2014 and later tumbled 85.84% in 2016.
  • Tracing TENX's Depreciation & Amortization (CF) over 5 years: stood at $37633.0 in 2013, then crashed by 44.2% to $21000.0 in 2014, then surged by 48.69% to $31224.0 in 2015, then tumbled by 85.84% to $4421.0 in 2016, then tumbled by 31.64% to $3022.0 in 2017.
  • Business Quant data shows Depreciation & Amortization (CF) for TENX at $3022.0 in Q4 2017, $3143.0 in Q3 2017, and $3424.0 in Q2 2017.